Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a Randomized, Single-Blind, Placebo-Controlled, 12-week Escalating Dose Study to Assess the Safety, Tolerability and Clinical Activity of 3 Concentrations of Locally Applied MBN-101 to Infected Bone Sites

NCT02436876 is registered in ClinicalTrials.gov with Microbion Corporation as lead sponsor.

NCT NCT02436876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02436876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a Randomized, Single-Blind, Placebo-Controlled, 12-week Escalating Dose Study to Assess the Safety, Tolerability and Clinical Activity of 3 Concentrations of Locally Applied MBN-101 to Infected Bone Sites
Lead sponsor
Microbion Corporation
Phase
Phase 2
Overall status
Completed
Start date
May 24, 2016
Completion date
July 26, 2018
Enrollment
29 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

bacterial infection